Researchers at Cleveland Clinic intend to expand their study of a novel vaccine designed to prevent triple-negative breast cancer.An ongoing phase 1A clinical trial — expected to conclude in the fourth quarter of this year — is investigating the vaccine for patients who completed treatment for early-stage, triple-negative breast cancer within the past 3 years and remain tumor free but
United States (National)